Arizona Center for Cancer Care Marks an Extraordinary Milestone
Arizona Center for Cancer Care (AZCCC) today announced its 100th patient treated with GammaTile® Therapy, a Surgically Targeted Radiation Therapy (STaRT) for brain tumors.
GT Medical Technologies Announces First Patient Enrolled in GESTALT Trial of GammaTile® Therapy for Newly Diagnosed Glioblastoma Brain Tumors
Enrolling Newly Diagnosed Patients with Glioblastoma in the GESTALT Clinical Trial
Kettering Health to offer new therapy that makes fighting brain tumors easier
Kettering Health is now the first provider in the Dayton area to offer GammaTile Therapy.
For his invention of GammaTile® Therapy used to treat operable brain tumors, David Brachman, M.D. is the 2022 winner of the Mensa Foundation’s Copper Black Award for Creative Achievement.
Tampa General Hospital Offers New Treatment for Recurrent Brain Cancer to Improve Quality of Life
Tampa General Hospital and USF Health Morsani College of Medicine physicians are the first in Hillsborough County to bring patients experiencing recurring brain tumors a groundbreaking treatment.
GT Medical Technologies Earns ISO and MDSAP Certifications
GT Medical Technologies announced today that it has earned the International Organization for Standardization (ISO) 13485:2016 certification from GMED. The certification demonstrates the company’s compliance with medical device quality management system requirements under the Medical Device Single Audit Program (MDSAP).
Shane H. Brown Joins GT Medical Technologies as Chief Commercial Officer
Shane Brown has joined GT Medical Technologies as its chief commercial officer. In this role, he will oversee all aspects of the company’s commercial strategies to drive growth and adoption of …
GT Medical Technologies Honored as Gold Stevie® Award Winner in 2022 American Business Awards®
GT Medical Technologies, Inc. announced today it was named Company of the Year for Health Products & Services in the 2022 American Business Awards. This honor acknowledges GT Medical Technologies’ pioneering technology GammaTile® Therapy, FDA-cleared for treating newly diagnosed malignant and recurrent brain tumors.
GT Medical Technologies Announces the Presentation of Clinical Data on GammaTile® Therapy in the Treatment of Recurrent Glioblastomas at the 2022 American Association of Neurological Surgeons Scientific Meeting
GT Medical Technologies, Inc. announced today that new data on the company’s innovative GammaTile Therapy for patients with operable brain tumors will be presented via an oral, live presentation at the 2022 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Philadelphia, PA. The abstract will provide the first report of clinical outcomes for recurrent glioblastoma patients treated with FDA-cleared GammaTile Therapy.
GT Medical Technologies Announces 2021 GammaTile® Therapy ELITE Member Roster for Use of Its Innovative Brain Tumor Treatment
GT Medical Technologies Inc., creators of GammaTile Therapy, a Surgically Targeted Radiation Treatment for operable brain tumors, today announced its 2021 roster of ELITE Distinguished Brain Tumor Specialists that have completed 10 or more GammaTile Therapy procedures in 2021.